Research Article

30-Day and 1-Year Mortality after Transcatheter Aortic Valve Replacement: The Impact of Balloon Aortic Valvuloplasty as a Bridging Therapy in a Portuguese Tertiary Center

Table 2

Baseline characteristics of study population.

VariableOverall (n = 800)wBAV group (n = 33)woBAV group (n = 767) value

Age, years83(8)82(7.5)83(7.8)0.492
Male gender360(45%)9(27%)351(46%)0.040
Hypertension670(84%)27(82%)646(84%)0.138
Diabetes mellitus286(36%)12(36%)275(36%)0.907
Active smoking112(14%)4(12%)110(14%)0.542
Coronary artery disease334(42%)13(39%)321(42%)0.806
Previous MI125(16%)6(18%)119(16%)0.360
Previous CABG107(13%)2(6%)105(14%)0.419
Peripheral artery disease127(16%)5(15%)122(16%)0.982
Previous stroke85(11%)5(15%)80(10%)0.364
Atrial fibrillation263(33%)18(55%)245(32%)0.006
Previous pacemaker80(10%)5(15%)75(10%)0.222
Chronic lung disease172(22%)5(15%)167(21%)0.615
Hemodialysis20(2.5%)0020(2.6%)0.551
Bicuspid aortic valve25(3.1%)1(3%)24(3.1%)0.342
EuroScore II4.2(4.6)6.9(6.7)4.1(4.3)0.001
STS score4.3(3.8)5.5(5.6)4.2(3.7)0.022
Clinical findings
 BMI, kg/m227(6)26.7(6.2)26.6(5.4)0.983
 Basal NYHA class2.8±0.5303(1)0.075
 Hb, g/dL11.9±1.811.4±1.711.9±1.80.087
 Cr, mg/dL1.1(0.6)1(0.6)1.1(0.6)0.768
 GFR, mL/min/1.73 m246(12)]41.5(13)47(14)0.227
 HbA1c, %5.7(0.8)5.8(0.7)5.7(1)0.814
 NT-proBNP, pg/mL1916(3986)2352(13647)1911(38890.79
 Mean AG (mmHg)48(15)45(13)48(15)0.832
 Maximum AG (mmHg)78(14)71(36)78(12)0.514
 AVA (cm2)0.7(0.3)0.6(0.35)0.7(0.30)0.215
 LVEF <50%171(22%)10(32%)161(21%)0.156
 LVEF <40%86(11%)8(26%)78(10%)0.015
 AVCS2104(1738)2659(2371)2100(1704)0.921

AG, aortic gradient; AVA, anatomic valve area; AVCS, aortic valve calcium score; BMI, body mass index; CABG, coronary artery bypass graft; GFR, glomerular filtration rate; LVEF, left ventricular ejection fraction; MI, myocardial infarction; NYHA, New York Heart Association; STS, Society of Thoracic Surgeons. Fisher’s exact test was used. Statisticially significant p values (<0.05) are highlighted in bold.